Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. 1993

E Kling, and S Bieg, and M Boehme, and W A Scherbaum
Abteilung Innere Medizin 1, Universität Ulm.

To determine the value of soluble intercellular adhesion molecule 1 (sICAM-1) as a measure of disease activity in patients with systemic lupus erythematosus (SLE), 25 patients with SLE were studied in an active and in a less active state. Disease activity was assessed according to the New York Hospital for Special Surgery System (NYHSS) score. The levels of sICAM-1 were significantly higher in an active than in a less active state of the disease (P < 0.001). The correlation between ICAM and the NYHSS score was r = 0.3412 (P < 0.001) and that between NYHSS index and soluble interleukin-2 receptors (sIL-2R) was r = 0.6620 (P < 0.001). There was a good correlation between levels of sICAM-1 and sIL-2R (r = 0.6792, P < 0.001). Both sICAM-1 and sIL-2R were positively and significantly correlated with an increase in the erythrocyte sedimentation rate, but only sIL-2R levels were significantly correlated with increased dsDNA antibodies and with a decrease in serum complement factor C3. Our data suggest that sICAM-1 reflects disease activity in patients with SLE, but this parameter per se should not be used to guide the therapeutic decision in SLE patients suspected of suffering from exacerbation of disease.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015815 Cell Adhesion Molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis. Cell Adhesion Molecule,Intercellular Adhesion Molecule,Intercellular Adhesion Molecules,Leukocyte Adhesion Molecule,Leukocyte Adhesion Molecules,Saccharide-Mediated Cell Adhesion Molecules,Saccharide Mediated Cell Adhesion Molecules,Adhesion Molecule, Cell,Adhesion Molecule, Intercellular,Adhesion Molecule, Leukocyte,Adhesion Molecules, Cell,Adhesion Molecules, Intercellular,Adhesion Molecules, Leukocyte,Molecule, Cell Adhesion,Molecule, Intercellular Adhesion,Molecule, Leukocyte Adhesion,Molecules, Cell Adhesion,Molecules, Intercellular Adhesion,Molecules, Leukocyte Adhesion

Related Publications

E Kling, and S Bieg, and M Boehme, and W A Scherbaum
May 1994, European journal of haematology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
January 1996, Clinical rheumatology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
January 1992, Contributions to nephrology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
July 1993, Clinical immunology and immunopathology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
July 1993, Clinical immunology and immunopathology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
January 1994, Clinical and experimental rheumatology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
January 2002, Rheumatology international,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
May 1997, Vnitrni lekarstvi,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
November 2007, Clinical rheumatology,
E Kling, and S Bieg, and M Boehme, and W A Scherbaum
April 2007, The Journal of rheumatology,
Copied contents to your clipboard!